Instituto Rosenbusch S.A. (ROSE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Instituto Rosenbusch S.A. (ROSE) has a cash flow conversion efficiency ratio of -1.542x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AR$811.18 Million ≈ $586.98K USD) by net assets (AR$-526.19 Million ≈ $-380.75K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check Instituto Rosenbusch S.A. strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Instituto Rosenbusch S.A. - Cash Flow Conversion Efficiency Trend (2000–2025)
This chart illustrates how Instituto Rosenbusch S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. See Instituto Rosenbusch S.A. book value and equity for net asset value and shareholders' equity analysis.
Instituto Rosenbusch S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Instituto Rosenbusch S.A. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mantle Minerals Ltd
AU:MTL
|
-0.118x |
|
TIMES CHINA HLDGS HD -10
F:T2H
|
N/A |
|
Mint Corp
V:MIT
|
0.055x |
|
Maple Peak Investments Inc
V:MAP
|
-0.062x |
|
China Natural Resources Inc
NASDAQ:CHNR
|
-0.048x |
|
Golden Goliath Resources Ltd.
V:GNG
|
-0.262x |
|
Manchester and London Investment Trust plc
LSE:MNL
|
-0.004x |
|
PMPG Polskie Media S.A.
WAR:PGM
|
-0.105x |
Annual Cash Flow Conversion Efficiency for Instituto Rosenbusch S.A. (2000–2025)
The table below shows the annual cash flow conversion efficiency of Instituto Rosenbusch S.A. from 2000 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Instituto Rosenbusch S.A..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | AR$-526.19 Million ≈ $-380.75K |
AR$409.89 Million ≈ $296.60K |
-0.779x | -531.50% |
| 2024-12-31 | AR$3.99 Billion ≈ $2.89 Million |
AR$720.31 Million ≈ $521.22K |
0.181x | +147.75% |
| 2023-12-31 | AR$4.55 Billion ≈ $3.29 Million |
AR$331.37 Million ≈ $239.78K |
0.073x | -40.74% |
| 2022-12-31 | AR$400.51 Million ≈ $289.81K |
AR$49.25 Million ≈ $35.64K |
0.123x | -58.04% |
| 2021-12-31 | AR$199.19 Million ≈ $144.13K |
AR$58.37 Million ≈ $42.24K |
0.293x | -34.20% |
| 2020-12-31 | AR$147.69 Million ≈ $106.87K |
AR$65.78 Million ≈ $47.60K |
0.445x | -13.10% |
| 2019-12-31 | AR$115.52 Million ≈ $83.59K |
AR$59.20 Million ≈ $42.84K |
0.513x | +439.11% |
| 2018-12-31 | AR$145.95 Million ≈ $105.61K |
AR$-22.06 Million ≈ $-15.96K |
-0.151x | -272.55% |
| 2017-12-31 | AR$86.58 Million ≈ $62.65K |
AR$-3.51 Million ≈ $-2.54K |
-0.041x | -121.32% |
| 2016-12-31 | AR$83.24 Million ≈ $60.23K |
AR$15.84 Million ≈ $11.46K |
0.190x | +252.20% |
| 2015-12-31 | AR$70.62 Million ≈ $51.10K |
AR$-8.83 Million ≈ $-6.39K |
-0.125x | -192.60% |
| 2014-12-31 | AR$68.24 Million ≈ $49.38K |
AR$9.21 Million ≈ $6.67K |
0.135x | -32.36% |
| 2011-12-31 | AR$56.25 Million ≈ $40.70K |
AR$11.23 Million ≈ $8.12K |
0.200x | +96.02% |
| 2010-12-31 | AR$50.20 Million ≈ $36.32K |
AR$5.11 Million ≈ $3.70K |
0.102x | +352.72% |
| 2009-12-31 | AR$46.95 Million ≈ $33.97K |
AR$1.06 Million ≈ $764.13 |
0.022x | -87.71% |
| 2008-12-31 | AR$45.65 Million ≈ $33.03K |
AR$8.36 Million ≈ $6.05K |
0.183x | +811.58% |
| 2007-12-31 | AR$37.50 Million ≈ $27.13K |
AR$753.00K ≈ $544.87 |
0.020x | -65.96% |
| 2006-12-31 | AR$35.97 Million ≈ $26.03K |
AR$2.12 Million ≈ $1.54K |
0.059x | -61.58% |
| 2005-12-31 | AR$34.13 Million ≈ $24.70K |
AR$5.24 Million ≈ $3.79K |
0.154x | -9.98% |
| 2003-12-31 | AR$28.27 Million ≈ $20.45K |
AR$4.82 Million ≈ $3.49K |
0.171x | +122.37% |
| 2002-12-31 | AR$24.17 Million ≈ $17.49K |
AR$1.85 Million ≈ $1.34K |
0.077x | +268.10% |
| 2000-12-31 | AR$11.90 Million ≈ $8.61K |
AR$248.00K ≈ $179.45 |
0.021x | -- |
About Instituto Rosenbusch S.A.
Instituto Rosenbusch S.A. manufactures and sells veterinary products in Argentina. The company offers biological products, including products for reproductive-respiratory complex, IBR, BVD, brucelosis, carbuncle, and other diseases; clostridial vaccines; vaccines for cattle, sheep, goats, horses, and dogs; and products for the prevention of pneumonia and calve diarrhea, and cattle infectious kera… Read more